Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23495232 | 1.00 | TP53 (0.78) | TP53MAPTKDM4EUSP2TSHR | |
| SCHEMBL23495226 | 0.90 | TP53 (0.82) | TP53MAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL29436179 | 0.90 | TP53 (0.82) | TP53MAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL29436263 | 0.83 | TP53 (0.59) | TP53MAPTKDM4ETSHRALDH1A1 | |
| SCHEMBL23495429 | 0.83 | TP53 (0.59) | TP53MAPTKDM4ETSHRALDH1A1 | |
| SCHEMBL23495436 | 0.83 | KDM4E (0.72) | TP53MAPTKDM4ETSHRALDH1A1 | |
| SCHEMBL29436218 | 0.83 | KDM4E (0.72) | TP53MAPTKDM4ETSHRALDH1A1 | |
| SCHEMBL23495340 | 0.81 | TP53 (0.68) | TP53MAPTKDM4EUSP2TSHR | |
| SCHEMBL23495320 | 0.81 | MAPT (0.79) | TP53MAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL23297317 | 0.80 | MEN1 (0.60) | TP53MAPTKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340526-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12415794-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20230293518-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-3877052-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20220081410-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2022-03-17 | — | — | US | disclosed |
| US-11236065-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPECUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293518-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | TP53 4843/4885MAPT 1863/4885KDM4E 3081/4885 |
| US-20220081410-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | TP53 4800/4885MAPT 1810/4885KDM4E 3514/4885 |
| US-12415794-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | TP53 4800/4885MAPT 1810/4885KDM4E 3514/4885 |
| US-11236065-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | TP53 4800/4885MAPT 1810/4885KDM4E 3514/4885 |
| US-20250340526-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | TP53 4800/4885MAPT 1810/4885KDM4E 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.